Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trialHiddo J.L. Heerspink, Elvino Barros, C. David Sjöström et al.|European Heart Journal|2021Cited by 122
Mutation Update and Genotype-Phenotype Correlations of Novel and Previously Described Mutations in<i>TPM2</i>and<i>TPM3</i>Causing Congenital MyopathiesM. Marttila, Carina Wallgren‐Pettersson, Enrico Bertini et al.|Human Mutation|2014Cited by 111
A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney functionHiddo J.L. Heerspink, Dánae Duana Ávila, David Z.I. Cherney et al.|Kidney International|2021Cited by 95